📰 4 sources covering this story

Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame

First covered 8 hrs ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

The Danish drugmaker also revealed an improved outlook for the year.

Reuters1 hrs ago

Novo outlook hike falls flat as Wegovy pill sales fail to impress Reuters

Quartz4 hrs ago

The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit

CNBC🏁 first to report8 hrs ago

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.